Spironolactone vs Tirzepatide: side-by-side comparison
Spironolactone (Potassium-sparing diuretic / aldosterone antagonist) and Tirzepatide (GIP/GLP-1 dual receptor agonist) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Spironolactone | Tirzepatide |
|---|---|---|
| Therapeutic class | Potassium-sparing diuretic / aldosterone antagonist | GIP/GLP-1 dual receptor agonist |
| CAS | 52-01-7 | 2023788-19-2 |
| ATC | C03DA01 | A10BX16 |
| Molecular weight | 416.57 g/mol | 4813.5 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Spironolactone and Tirzepatide share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Spironolactone acts by a different mechanism than Tirzepatide, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Spironolactone: Spironolactone competitively blocks the mineralocorticoid (aldosterone) receptor in the distal tubule of the kidney, reducing sodium reabsorption and potassium excretion. Tirzepatide: Tirzepatide binds with high affinity to the GIP receptor and to the GLP-1 receptor.
Indications compared
Spironolactone: Spironolactone is approved for heart failure with reduced ejection fraction, primary hyperaldosteronism, resistant hypertension, oedema in cirrhosis or nephrotic syndrome, and certain potassium-loss states. Tirzepatide: Tirzepatide is approved in adults with type 2 diabetes mellitus, as monotherapy or in combination with other antidiabetic agents, to improve glycaemic control.
Safety profile
Spironolactone: Common adverse effects include hyperkalaemia (especially with renal impairment or ACE inhibitors), gynaecomastia in men, menstrual irregularities in women, and dizziness from blood pressure effects. Tirzepatide: The most common adverse effects are gastrointestinal: nausea, diarrhoea, vomiting, decreased appetite, constipation and abdominal discomfort, generally mild to moderate and most pronounced during dose escalation.
Frequently asked questions
Is Spironolactone better than Tirzepatide? ▾
Spironolactone and Tirzepatide are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Spironolactone and Tirzepatide be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Spironolactone
Products with Tirzepatide
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.